The Role of Cyclosporine in the Treatment of Severe Ulcerative Colitis in the Pediatric Population: A Narrative Review Exploring Known Strategies and New Possibilities
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cyclosporine offers rescue therapy for severe pediatric ulcerative colitis (ASUC), acting as a crucial bridge to biologics and novel treatments when steroids fall short.
Area Of Science
- Pediatric Gastroenterology
- Immunology
- Pharmacology
Background
- Systemic glucocorticosteroids (GCSs) reduce mortality in acute severe ulcerative colitis (ASUC) but have limited long-term efficacy and significant adverse effects.
- Cyclosporine serves as a second-line 'rescue therapy' for pediatric ASUC, aiming to control symptoms, prevent complications like toxic megacolon, and delay colectomy.
- Current research on novel cyclosporine strategies in pediatric ASUC is limited.
Purpose Of The Study
- To review current evidence on cyclosporine's use as induction or rescue therapy in pediatric ASUC.
- To explore the integration of cyclosporine with biologic and biosimilar strategies.
- To highlight cyclosporine's evolving role as a bridge to advanced therapies.
Main Methods
- Literature review of existing studies on cyclosporine in pediatric ASUC.
- Analysis of cyclosporine's efficacy as induction and rescue therapy.
- Exploration of future therapeutic integrations and bridging strategies.
Main Results
- Cyclosporine can alleviate ASUC symptoms and postpone colectomy, providing time for patient preparation and initiation of chronic treatments.
- It acts as an induction agent, bridging patients to maintenance therapies like biologics.
- Evidence for novel strategies and long-term outcomes in pediatric ASUC is still developing.
Conclusions
- Cyclosporine remains a vital rescue therapy for pediatric ASUC, offering a critical window for managing severe disease.
- Its role is expanding as a bridge to biologics and targeted therapies, addressing limitations of traditional treatments.
- Further research is needed to optimize cyclosporine use and integration with emerging therapeutic modalities in pediatric ASUC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...